EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MyMD Pharmaceuticals's enterprise value is $2.74 Mil.
MyMD Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-17.32 Mil. Therefore, MyMD Pharmaceuticals's EV-to-EBITDA for today is -0.16.
The historical rank and industry rank for MyMD Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
MYMD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -140.48 Med: 0 Max: 0.22
Current: -0.16
During the past 4 years, the highest EV-to-EBITDA of MyMD Pharmaceuticals was 0.22. The lowest was -140.48. And the median was 0.00.
MYMD's EV-to-EBITDA is ranked worse than 100% of 452
companies
in the Biotechnology industry
Industry Median: 9.47
vs MYMD: -0.16
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
MyMD Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for MyMD Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MyMD Pharmaceuticals's EV-to-EBITDA
For the Biotechnology subindustry, MyMD Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MyMD Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MyMD Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MyMD Pharmaceuticals's EV-to-EBITDA falls into.
MyMD Pharmaceuticals's current Enterprise Value is $2.74 Mil.
MyMD Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
MyMD Pharmaceuticals's PE Ratio for today is calculated as:
MyMD Pharmaceuticals's share price for today is $1.96.
MyMD Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.570.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of MyMD Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
MyMD Pharmaceuticals (MyMD Pharmaceuticals) Business Description
MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and a monoamine oxidase enzyme type B.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYMD has been successfully added to your 